Shanghai CP Guojian Pharmaceutical Co Ltd (CPGJ) is a biopharmaceutical company that was formed in January 1998. The company headquarters are based in Zhangjiang Hi-tech Park, Pudong New Area in Shanghai and it is involved in a range of new
The Polymer Technology Group, Inc. (www.polymertech.com), a preeminent biomaterials company, announced today that it has in-licensed a family of bioresorbable polymers from Hillsborough, N.J.-based Bezwada Biomedical L.L.C., whose founder and president, Rao Bezwada, Ph.D., will also serve as a consultant
A new version of Allen Technologies' Vigo™ in-room Interactive Patient Care (IPC) solution helps hospitals improve scores for Hospital Process of Care Measures, mitigate Medicare Never Events, and facilitate requests from patients to participate more fully in their treatment decisions.
PsychoGenics Inc., announced the appointment of Bavani Shankar, as Vice President of Corporate Development. This appointment reflects the company's growth and expansion into new areas of CNS drug discovery and development. (PRWeb May 28, 2008) Read the full story at
INC Research, a therapeutically-focused contract research organization (CRO) with a process for delivering reliable results, today announced that David Gill and William Hall have been elected to its Board of Directors. Both new members bring necessary expertise to help guide
Shire has announced that Elaprase, a human enzyme replacement therapy for the treatment of Hunter syndrome, has received approval from the Brazilian Regulatory Agency, Agencia Nacional de Vigilancia Sanitaria.
Santarus, a specialty pharmaceutical company, has achieved a $2.5 million regulatory milestone under its over-the-counter license agreement with Schering-Plough Healthcare Products.
The Ensign Group, the parent company of the Ensign group of skilled nursing, rehabilitative care services and assisted living companies, has completed the purchase of an 83-bed skilled nursing facility in Draper, Utah for approximately $3 million.
Alnylam Pharmaceuticals and Takeda Pharmaceutical Company have formed a strategic platform alliance in RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional therapeutic areas.
EpiCept has submitted the documentation to support a re-examination of its marketing authorization application in Europe for Ceplene to the Committee for Medicinal Products for Human Use.
Inovio Biomedical has entered into a license agreement with Advanced BioScience Laboratories, so that ABL may provide advanced electroporation delivery of DNA vaccines for its research uses.
Favrille has announced results from the company's Phase III registration trial of Specifid following Rituxan in patients with follicular B-cell non-Hodgkin's lymphoma.
Yissum, the technology transfer company of the Hebrew University of Jerusalem, has introduced a novel device that enhances the diagnostic value of saliva. The device is said to enable the detection of various low-abundance biomarkers in human saliva.
ZymoGenetics has announced that the FDA has approved a prior approval supplement application for a 20,000 international unit vial of Recothrom Thrombin, topical and also approved co-packaging of the 20,000-IU vial with the ZymoGenetics Spray Applicator Kit.
Orexigen Therapeutics has announced that the US Patent and Trademark Office has issued US patent for claims covering sustained release compositions of bupropion and naltrexone combined in a single dosage form.
Discovery Laboratories has entered into a new committed equity financing facility with Kingsbridge Capital, a private investment group, in which Kingsbridge has committed to provide up to $60 million of capital over a three-year period through the purchase of newly-issued
